CRISPR Therapeutics AG 8-K

What Happened
CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2025 in a press release issued February 12, 2026. The company furnished the press release as Exhibit 99.1 to the Form 8-K; the filing notes this furnished material is not “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings. The Form 8-K was signed by CEO Samarth Kulkarni.

Key Details

• Announcement date: February 12, 2026.
• Period covered: quarter and fiscal year ended December 31, 2025.
• Press release furnishing: Exhibit 99.1 to the Form 8-K contains the full financial results and business highlights.
• Legal note: the information is furnished (not filed) and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into other SEC filings.

Why It Matters
This 8-K signals CRISPR has released its latest earnings and year-end business update; investors should review the Exhibit 99.1 press release for specific metrics such as revenue, net income/loss, cash position, and any guidance or program updates. Because the release is furnished rather than filed, the company is providing results and highlights to the market but has limited Section 18 liability for the disclosed content. For audited financial statements or formal filings, investors should watch for the company’s periodic reports (e.g., Form 10-K) or subsequent filings that formally incorporate financial data.